Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous anti-CLL-1-CAR T lymphocytes BG1805

A preparation of autologous T lymphocytes expressing a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) C-type-lectin-like molecule-1 (CLL-1; CLL1; C-type lectin domain family 12 member A; CLEC12A), with potential immunomodulating and antineoplastic activities. Upon administration, the autologous anti-CLL-1-CAR T lymphocytes BG1805 specifically target and bind to CLL-1-expressing tumor cells. This induces selective toxicity in CLL-1-expressing tumor cells. CLL-1, a member of the C-type lectin/C-type lectin-like domain (CTL/CTLD) superfamily, is overexpressed in leukemic stem cells (LSCs) and plays an important role in disease progression and relapse in myeloid malignancies.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:autologous anti-CLL-1-CAR T cells BG1805
autologous anti-CLL1 CAR T Cells BG1805
autologous anti-CLL1 CAR-T cells BG1805
Code name:BG 1805
BG-1805
BG1805
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search